Status:
TERMINATED
Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection
Lead Sponsor:
Johns Hopkins University
Collaborating Sponsors:
Eiger BioPharmaceuticals
Conditions:
Sars-CoV-2 Infection
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
This is a phase 2b prospective, randomized, single-blind, controlled trial of a single subcutaneous injection of peginterferon lambda-1a versus placebo for prevention of SARS-CoV-2 infection in non-ho...
Eligibility Criteria
Inclusion
- Willing and able to provide written informed consent
- Peripheral capillary oxygen saturation (SpO2) ≥ 95% on room air at screening
- Age ≥18 years
Exclusion
- Hospitalized or impending hospitalization at the time of screening
- Symptoms of cough, fever or shortness of breath within 72 hours
- Prior or current treatment with other experimental or approved agents targeting SARS-CoV-2 or SARS-CoV-1
- Positive pregnancy test
- Active autoimmune disease or sarcoidosis (with the exception of controlled thyroid disease)
- Active decompensated liver disease (ascites, encephalopathy)
- Active congestive heart failure
Key Trial Info
Start Date :
June 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 24 2021
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04344600
Start Date
June 29 2020
End Date
September 24 2021
Last Update
July 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287